Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986089 in healthy adults
NCT02145234Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Feb 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) (2 arms), sponsored by Roche. Primary endpoint: Incidence of Adverse Events at 148 days. Started Jun 2014; status: completed.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02145234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145234.